Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
A phase II trial by DART, SWOG, and NCI investigates the efficacy of anti-CTLA-4 and PD-1 therapies in treating clear cell carcinomas of the ovary, endometrium, and cervix. This study contributes to understanding immunotherapy's role in rare cancer types.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.